abrdn plc Buys Shares of 1,452,741 Oculis Holding AG (NASDAQ:OCS)

abrdn plc bought a new stake in Oculis Holding AG (NASDAQ:OCS) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,452,741 shares of the company’s stock, valued at approximately $15,980,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Barclays PLC acquired a new position in Oculis in the second quarter valued at about $44,000. Compagnie Lombard Odier SCmA raised its position in shares of Oculis by 47.3% during the fourth quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company’s stock worth $1,053,000 after purchasing an additional 30,750 shares during the period. Finally, Wolverine Asset Management LLC bought a new position in shares of Oculis during the 3rd quarter valued at about $77,000. Institutional investors and hedge funds own 22.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. HC Wainwright cut their price objective on Oculis from $29.00 to $28.00 and set a “buy” rating on the stock in a report on Wednesday. Wedbush reiterated an “outperform” rating and set a $29.00 price objective on shares of Oculis in a report on Wednesday, March 6th. Robert W. Baird cut their price objective on Oculis from $64.00 to $35.00 and set an “outperform” rating on the stock in a report on Tuesday, March 19th. Finally, Chardan Capital reiterated a “buy” rating and set a $30.00 price objective on shares of Oculis in a report on Tuesday, March 19th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $29.14.

Oculis Stock Performance

NASDAQ:OCS opened at $11.98 on Thursday. Oculis Holding AG has a twelve month low of $9.05 and a twelve month high of $14.50. The stock’s 50 day moving average price is $11.89 and its two-hundred day moving average price is $11.22. The company has a quick ratio of 5.29, a current ratio of 5.29 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS) last posted its quarterly earnings results on Monday, March 18th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.04. The company had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.28 million. Analysts predict that Oculis Holding AG will post -1.75 EPS for the current year.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.